[1] Chen, W.; Zheng, R.; Zhang, S. Report of cancer incidence and mortality in Cina, 2010. China Cancer 2014, 2, 61.
[2] Han, Z. J.; Deng, S. K. Advances in targeted therapy for non-small cell lung cancer. Qinghai Med. J. 2019, 49, 77–80.
[3] Mcloughlin, E. M.; Gentzler, R. D. Epidermal Growth Factor Receptor Mutations. Thoracic Surg. Clin. 2020, 30, 127–136.
[4] Bishayee, S. Role of conformational alteration in the epidermal growth factor receptor (EGFR) function. Biochem. Pharmacol. 2000, 60, 1217–1223.
[5] Heon, S.; Yeap, B. Y.; Lindeman, N. I.; Joshi V .A.; Butaney, M.; Britt, G. J.; Costa, D. B.; Rabin, M. S.; Jackman, D. M.; Johson, R. E. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clin. Cancer Res. 2012, 18, 4406–4414.
[6] Okamoto, I. Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy. FEBS J. 2010, 277, 309–315.
[7] Mok, T. S.; Wu, Y. L.; Thongprasert, S.; Yang, C. H.; Chu, D. T.; Saijo, N.; Sunpaweravong, P.; Han, B. H.; Margono, B.; Ichinose, Y.; Nishiwaki, Y.; Ohe, Y.; Yang, J. J.; Chewaskulyong, B.; Jiang, H. Y.; Duffield, E. L.; Watkins, C. L.; Armour, A. A.; Fukuoka, M. Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma. New. Engl. J. Med. 2009, 361, 947–957.
[8] Shepherd, F. A.; Pereira, J. R.; Ciuleanu, T.; Tan, E. H.; Hirsh, V.; Thongprasert, S.; Campos, D.; Maoleekoonpiroj, S.; Smylie, M.; Martins, R.; van Kooten, M.; Dediu, M.; Findlay, B.; Tu, D. S.; Johnston, D.; Bezjak, A.; Clark, G.; Santabárbara, P.; Seymour, L. Erlotinib in previously treated non–small-cell lung cancer. New Engl. J. Med. 2005, 353, 123–132.
[9] Zhao, Q. Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer. Oncol. Rep. 2012, 27, 2066–2072.
[10] Blackwell, K. L.; Burstein, H. J.; Storniolo, A. M.; Rugo, H.; Sledge, G.; Koehler, M.; Ellis, C.; Casey, M.; Vukelja, S.; Bischoff, J.; Baselga, J.; O'Shaughnessy, J. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-Positive, trastuzumab-refractory metastatic breast cancer. J. Clin. Oncol. 2010, 28, 1124–1130.
[11] Agustoni, F.; Platania, M.; Vitali, M.; Zilembo, N.; Haspinger, E. R.; Sinno, V.; Gallucci, R.; Braud, F. D.; Garassino, M. C. Emerging toxicities in the treatment of non-small cell lung cancer: Ocular disorders. Cancer Treat. Rev. 2014, 40, 197–203.
[12] Schleger, C.; Heck, R.; Steinberg, P. The role of wild-type and mutated N-ras in the malignant transformation of liver cells. Mol. Carcinogen. 2000, 28, 31–41.
[13] Li, D.; Shimamura, T. Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell 2007, 12, 81–93.
[14] Smaill, J. B.; Showalter, H. D.; Zhou, H.; Bridges, A. J.; McNamara, D. J.; Fry, D. W.; Nelson, J. M.; Sherwood, V.; Vincent, P. W.; Roberts, B. J.; Ellitt, W. L.; Denny, W. A. Tyrosine Kinase Inhibitors. 18. 6-Substituted 4-Anilinoquinazolines and 4-Anilinopyrido[3,4-d]- pyrimidines as Soluble, Irreversible Inhibitors of the Epidermal Growth Factor Receptor. J. Med. Chem. 2001, 44, 429–440.
[15] Yoshimura, N.; Kudoh, S.; Kimura, T.; Mitsuoka, S.; Matsuura, K.; Hirata, K.; Matsui, K.; Negoro, S.; Nakagawa, K.; Fukuoka, M. EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib. Lung Cancer 2006, 51, 363–368.
[16] Sequist, L. V.; Goldman, J. W.; Wakelee, H. A.; Camidge, D. R.; Yu, H. A.; Varga, A.; Solomon, B.; Oxnard, G. R.; Ou, S. I.; Papadimitrakopoulou, V. A.; Chao, B. H.; Liu, S. V. Reckamp, K. L.; Spira, A. I.; Piotrowska, Z.; Despain, D.; Karlovich, C.; Yurasov, S.; Soria, J. Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSCLC) patients (pts). J. Clin. Oncol. 2015, 33, 8001–8001.
[17] Oxnard, G. R.; Ramalingam, S. S.; Ahn, M.; Kim, S.; Yu, H. A.; Saka, H.; Horn, L.; Goto, K.; Ohe, Y.; Cantarini, M.; Frewer, P.; Lahn, M.; Yang, J. C. Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer. J. Clin. Oncol. 2015, 33, 2509–2509.
[18] Wang S. H.; Song, Y.; Liu, D. L. EAI045: The fouth-generation EGFR inhibitor overcoming T790M and C797S resistance. Cancer Lett. 2017, 385, 51–54.
[19] Engelhardt, H.; Bose, D.; Petronczki, M.; Scharn, D.; Bader, G.; Baum, A.; Bergner, A.; Chong, E.; Dobel, S.; Egger, G.; Engelhardt, C.; Ettmayer, P.; Fuchs, J. E.; Gerstberger, T.; Gonnella, N. C.; Grimm, A.; Grondal, E.; Haddad, N.; Hopfgartner, B.; Kousek, R.; Krawiec, M.; Kriz, M.; Lamarre, L.; Leung, J.; Mayer, M.; Patel, N. D.; Simov, B. P.; Reeves, J. T.; Schnitzer, R.; Schrenk, A.; Sharps, B.; Solca, F.; Stadtmuller, H.; Tan, Z. L.; Wunberg, T.; Zoephel, A.; Mcconnell, D. Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors. J. Med. Chem. 2019, 62, 10272–10293. |